ライフサイエンスコーパス: FAP

1 FAP (fibroblast activation protein) plays an important r

2 FAP expression is minimal or absent in most normal adult

3 FAP inhibition is investigated as a therapeutic option f

4 FAP is a new target molecule for PET imaging of various

5 FAP is overexpressed by cancer-associated fibroblasts of

6 FAP(+) cells of the LN anlagen express lymphotoxin beta

7 FAP-expressing HT1080hFAP cells were used to study compe

8 FAP-mediated collagen processing leads to increased coll

9 FAPs expressed desmosome proteins, including desmoplakin

10 FAPs isolated from the Pdgfra-Cre:Eyfp:Dsp(W/F) mouse he

11 Formaldehyde probe-1 (FAP-1) is capable of detecting physiologically relevant

12 stribution studies were performed on HT-1080-FAP tumor-bearing mice.

13 eriments on FAP-transfected HT-1080 (HT-1080-FAP) or on mouse FAP-expressing (HEK-muFAP) and CD26-exp

14 bserved on planar scintigraphy for a HT-1080-FAP-xenotransplanted mouse.

15 organic phase is an ionic liquid [P6,6,6,14][FAP]/toluene mixture.

16 9.7%), indeterminate colitis (n = 63, 1.7%), FAP (n = 223, 6%), Crohn's disease (n = 150, 4%), cancer

17 a polymer conjugate (an iBody) containing a FAP-specific inhibitor as the targeting ligand.

18 acid, fatty acid, and mineral profiles (AAP, FAP, and MP, respectively), as well as protein degradati

19 e is available from generators, which allows FAP-targeted endoradiotherapy.

20 OP) and fibroblast activation protein alpha (FAP) covalent inhibitors has led us to question whether

21 bryonic fibroblast activation protein-alpha (FAP)(+) progenitor.

22 ncoding fibroblast activation protein-alpha (FAP).

23 tion of fibroblast activation protein-alpha (FAP-alpha) were able to block CD44-mediated reactive oxy

24 Furthermore, preliminary studies in an FAP in vivo model at early stages of disease development

25 than 50 years were more likely to receive an FAP liver [odds ratio (OR) 1.94, confidence interval (CI

26 clerosis is a fibroinflammatory disease, and FAP was previously reported to be up-regulated in human

27 ipocyte 3T3-L1 and 3T3-F422A, while DPP4 and FAP inhibitors have no effect.

28 ed an inverse correlation between IFNAR1 and FAP levels.

29 hibitors of RIPK3, MLKL, p38 MAPK, PI3K, and FAP-alpha.

30 to identify subjects with desmoid tumors and FAP.

31 macrophage antibody), or (111)In-28H1 (anti-FAP antibody), respectively, with nonspecific controls i

32 arthritis was imaged with (111)In-28H1 (anti-FAP), (111)In-anti-F4/80-A3-1, and (111)In-RGD2.

33 Radioimmunoimaging with an anti-FAP antibody might be used to monitor the response to th

34 cotinamide ((99m)Tc-S-HYNIC)-conjugated anti-FAP antibody 28H1 at 2, 5, and 9 d after treatment.

35 nd PET with (111)In- and (89)Zr-labeled anti-FAP antibody 28H1 was performed in mice with CIA.

36 dy was to assess whether a radiolabeled anti-FAP antibody could be used to monitor the efficacy of tr

37 SPECT/CT imaging with the anti-FAP antibody (111)In-28H1 specifically visualized arthri

38 noimaging of activated fibroblasts with anti-FAP antibodies might be an attractive noninvasive imagin

39 t of quinoline-based PET tracers that act as FAP inhibitors (FAPIs) demonstrated promising results pr

40 and thus activates MG to a similar extent as FAPs based on single-chain variable fragments.

41 haracterization of the first self-assembling FAP split system, DiB-splits.

42 The quinoline-based FAP inhibitor (FAPI) PET tracer (68)Ga-FAPI-04 has been

43 The quinoline-based FAP-inhibitor PET tracer, (68)Ga-FAPI-04, has been previ

44 Accordingly, a variety of quinolone-based FAP inhibitors (FAPIs) coupled to chelators were develop

45 It has already been shown that DOTA-bearing FAP inhibitors (FAPIs) generate high-contrast images wit

46 Blocking FAP ciliation also enhanced myofiber regeneration after

47 gation; this effect was also blocked by both FAP-alpha and MLKL inhibitors.

48 nalyzed with clinical disability assessed by FAP stage score (stage 0-4) and compared to neurophysiol

49 xamine whether circulating CAF identified by FAP and alpha-SMA co-expression (cCAF) could be distingu

50 rved specificity in substrate recognition by FAP, but not by DPPIV or PREP.

51 We conclude that ciliary Hh signaling by FAPs orchestrates the regenerative response to skeletal

52 le structure of the ionic liquid [C18mim](+)[FAP](-) near its free surface was studied by complementa

53 al cells from patients with IBD, IBD-cancer, FAP-adenoma, and colorectal cancer, but not in patients

54 new imaging modality to investigate cardiac FAP.

55 A subset of cardiac FAPs, identified by the PDGFRA(pos):Lin(neg):THY1(neg):D

56 xin A2 (AnxA2) in the myofiber matrix causes FAP differentiation into adipocytes.

57 68, PD-L1 (programmed death-ligand 1), CD34, FAP (fibroblast activation protein), and cytokeratin in

58 fluorescence intensity assay for circulating FAP activity based on a recently identified natural subs

59 Clinically, FAP expression serves as an independent negative prognos

60 ibition constants but does not inhibit close FAP homologues dipeptidyl peptidase IV, dipeptidyl pepti

61 We identified consecutive FAP patients After duodenal resection, including pancrea

62 CPP FAP-310, a randomized, double-blind, Phase III trial was

63 In cultured FAPs, IL-4 inhibited Dex-induced conversion of FAPs into

64 In contrast, depleting FAP(+) FRCs during an ongoing influenza infection does n

65 As expected, depleting FAP(+) FRCs causes the loss of naive T cells, B cells, a

66 and demonstrated high uptake into different FAP-positive tumors in cancer patients.

67 nally, the assay was used to detect elevated FAP activity in human patients diagnosed with liver cirr

68 eviously, a panel of green- and red-emitting FAPs has been created from bacterial lipocalin Blc (name

69 ation of the FAPI framework enabled enhanced FAP binding and improved pharmacokinetics in most of the

70 Thirteen patients (11.4%) evidenced FAP disease but not before 6 years after DLT.

71 f both whole muscle and, to a lesser extent, FAPs, showed significant overlap with transcriptional pr

72 nostic ligand for metastasized cancer, FAPI (FAP inhibitor) tracers have recently been used to study

73 l subtype is novel and a corresponding FBN1+ FAP cell type was also found in single cell RNA-seq anal

74 The human FBN1+ FAP cell subtype is novel and a corresponding FBN1+ FAP

75 (average age 70.5 years) generated 50% fewer FAPs compared to young adults (25.0 years) and teenagers

76 atment arms: best (ie, longest time to first FAP-related event [rectal/pouch polyposis]), intermediat

77 167 nM), showed slightly lower affinity for FAP in vitro, whereas plasma protein binding was higher

78 he effectiveness of a chemical inhibitor for FAP in mice.

79 These findings suggest a novel role for FAP-mediated fibro-adipogenic diaphragm remodeling in ob

80 results show the iBody is a useful tool for FAP targeting in vitro and potentially also for specific

81 a general hallmark of tubular adenomas from FAP patients.

82 administration stimulated adipogenesis from FAP-EGFP.

83 Genetically removing cilia from FAPs inhibited intramuscular adipogenesis, both after in

84 yfp:Dsp(W/F) mice, indicating an origin from FAPs.

85 t sections demonstrated 3- and 8-fold higher FAP-positive fibroblast density in the border zone than

86 To understand how FAP-alpha is involved in this nonapoptotic death pathway

87 le influence of ozone (0 vs 40 ppb) on human FAP emissions, there was a strong influence of relative

88 Our study identifies FAP as a novel endogenous regulator of fibrosis and is t

89 isms in FSHD and highlighting the importance FAPs in this disease.

90 4, 11 of 15 FAPI derivatives showed improved FAP binding in vitro.

91 There were no differences (P>0.05) in FAP, AAP, and MP.

92 conclusion, daily sulindac administration in FAP patients significantly altered colorectal stem cell

93 cancer is the most common cause of death in FAP.

94 be effective in preventing cancer deaths in FAP.

95 logical evidence of sudomotor denervation in FAP.

96 ate that HuR activation is an early event in FAP-adenoma but is not present in IBD-dysplasia.

97 sed mortality and increased lung fibrosis in FAP-deficient mice compared with wild-type mice.

98 of intermediate-sized collagen fragments in FAP-deficient mouse lungs, consistent within vitrostudie

99 sed selectively in CAFs, drawing interest in FAP as a stromal target.

100 39 and rapamycin, decreased proliferation in FAP-COs, but also affected cell proliferation in wild-ty

101 Advanced duodenal polyposis stage in FAP requires consideration of duodenal resection to prev

102 P-low-specific transcription factor TCF21 in FAP-high CAFs decreases their ability to promote invasio

103 FAPs into adipocytes; this did not occur in FAPs expressing knockdown of the IL-4 receptor.

104 ical problem in high-risk patients including FAP population.

105 dipokine, increases with obesity and induces FAP proliferation.

106 ential to selectively and completely inhibit FAP in vivo.

107 , boronic acids) must be employed to inhibit FAP than for POP.

108 ully applied to FAP, as an overview of known FAP inhibitors confirmed our computational predictions t

109 ivated fibroblasts with a new (68)Ga-labeled FAP inhibitor ((68)Ga-FAPI-04) for PET imaging of fibrob

110 mpact of PET/CT imaging using (68)Ga-labeled FAP-inhibitors ((68)Ga-FAPI PET/CT) in 19 patients with

111 inistration of 150-250 MBq of (68)Ga-labeled FAP-specific tracers.

112 ation with late onset (>50 years; LateMet30) FAP (p = 0.0005).

113 French Ile107Val, Ser77Tyr, and LateVal30Met FAP showed more rapid and severe disease progression; on

114 (68)Ga-labeled chelator-linked FAP inhibitors (FAPIs) have been successfully applied to

115 ay to measure the rates of clathrin-mediated FAP-EGFR endocytosis stimulated with physiological EGF c

116 targeted fluorogen-activating peptide (Mito-FAP) to deliver a photosensitizer MG-2I dye exclusively

117 hermore, ATM inhibition exacerbated the Mito-FAP-induced mitochondrial dysfunction and sensitized cel

118 ght-mediated activation (660 nm) of the Mito-FAP-MG-2I complex led to a rapid loss of mitochondrial r

119 ng-sleeve shirts and pants produced 40% more FAPs relative to those wearing t-shirts and shorts.

120 Moreover, FAP-1 can visualize endogenous FA produced by lysine-spe

121 The iBody inhibits both human and mouse FAP with low nanomolar inhibition constants but does not

122 ransfected HT-1080 (HT-1080-FAP) or on mouse FAP-expressing (HEK-muFAP) and CD26-expressing (HEKCD26)

123 playing specific binding to human and murine FAP with a rapid and almost complete internalization.

124 mal proliferation specifically in APC-mutant FAP-COs.

125 erred to and followed at the French National FAP Reference Center from 1988 to 2010.

126 Coupling native FAP-EGFR expression with the high method sensitivity has

127 hepatic artery thrombosis compared with non-FAP transplanted patients.

128 mediated by the ability of FAP-high, but not FAP-low, CAFs to aggressively promote proliferation, inv

129 nteraction detection system as well as novel FAP-based sensors.

130 and that this is mediated by the ability of FAP-high, but not FAP-low, CAFs to aggressively promote

131 tively distinguish endopeptidase activity of FAP from that of other related enzymes such as prolyl en

132 of the study was to evaluate the activity of FAP via FAPI-positron emission tomography-computed tomog

133 ovel single mutation (Phe33Ile) in a case of FAP with vitreous amyloidosis from India is reported.

134 Prior studies established that depletion of FAP(+) cells inhibits tumor growth by augmenting antitum

135 sensor allowed femtomolar (fM) detection of FAP, a detection limit well adapted and promising for qu

136 ogies and for the therapeutic development of FAP inhibitors.

137 d provide support for further development of FAP(+) stromal cell-targeted therapies for the treatment

138 here could thus be utilized for diagnosis of FAP-related pathologies and for the therapeutic developm

139 t of 1 pedigree, confirming the diagnosis of FAP.

140 peptidase DPPIV, the extracellular domain of FAP can be released into circulation as a functional enz

141 Because of the high expression of FAP in arthritic joints, radioimmunoimaging of activated

142 strated to faithfully report the fraction of FAP-EGFR located in acidic endosomal/lysosomal compartme

143 These data distinguish the function of FAP(+) CASCs from other CASC subsets and provide support

144 Pharmacological inhibition of FAP adipogenesis arrests adipogenic replacement and dege

145 icability of this iBody for the isolation of FAP from cell lysates and blood serum as well as for its

146 biopsies were performed on the distal leg of FAP patients with a follow-up duration of 3.8 +/- 1.6 ye

147 tudies suggest that the circulating level of FAP correlates with the degree of tissue fibrosis.

148 estoration of FAP expression in the lungs of FAP-deficient mice decreases lung hydroxyproline content

149 for HuR inhibition as an effective means of FAP chemoprevention, with caution advised in the setting

150 HuR inhibition in APC(Min) mice, a model of FAP and colon cancer, diminished the number of small int

151 orescence staining confirmed the presence of FAP-positive myofibroblasts in the injured myocardium.

152 potential strategy to control progression of FAP-related intestinal polyposis.

153 Yet, quantification of FAP emissions from human beings remains limited, along w

154 The specific recognition of FAP is based on the interaction between folic acid recep

155 Conversely, restoration of FAP expression in the lungs of FAP-deficient mice decrea

156 The SGIIPGP 9.5 and SGIIVIP of FAP patients were significantly lower than those of age-

157 PET tracers for extended imaging studies of FAP-dependent diseases, we herein report the radiosynthe

158 ]FGlc-FAPI may allow extended PET studies of FAP-related diseases, such as cancer, but also arthritis

159 Adoptive transfer of FAP-CAR T cells also decreased tumor vascular density an

160 Adoptive transfer of FAP-CAR T cells also restrained autochthonous pancreatic

161 However, adoptive transfer of FAP-reactive T cells into mice bearing a variety of subc

162 tion of these cells, by adoptive transfer of FAP-targeted chimeric antigen receptor (CAR) T cells, re

163 l mimetic of TIMP3 blocked the conversion of FAPs into adipocytes, pointing to a strategy to combat f

164 Ps, IL-4 inhibited Dex-induced conversion of FAPs into adipocytes; this did not occur in FAPs express

165 -4/IL-13 signaling promotes proliferation of FAPs to support myogenesis while inhibiting their differ

166 dely studied in muscle diseases, the role of FAPs in adipogenic muscle loss is not well understood.

167 e results demonstrate the pathogenic role of FAPs in LGMD2B and establish these cells as therapeutic

168 ro by binding and competition experiments on FAP-transfected HT-1080 (HT-1080-FAP) or on mouse FAP-ex

169 , 260 children (aged 8-18 years) with IBS or FAP(S) were included in this study.

170 performed by therapists in pediatric IBS or FAP(S).

171 families with and without Cowden syndrome or FAP.

172 entafluoroethyl)trifluorophosphate ([P66614][FAP]) ILs.

173 emissions of fluorescent aerosol particles (FAPs) can influence the biological burden of indoor air.

174 Pharmacologic FAP inhibition decreases collagen internalization as exp

175 omponent of familial amyloid polyneuropathy (FAP) due to mutated transthyretin, with sudomotor failur

176 TR)-related familial amyloid polyneuropathy (FAP) is an autosomal dominant neurological disease, caus

177 tients with familial amyloid polyneuropathy (FAP) is described.

178 ntations of familial amyloid polyneuropathy (FAP) with transthyretin (TTR) mutations.

179 most common familial amyloid polyneuropathy (FAP), transthyretin (TTR) displays this role primarily a

180 rs from familial amyloidotic polyneuropathy (FAP) patients is a well-described technique and useful f

181 n (TTR) familial amyloidotic polyneuropathy (FAP; n = 20), (2) TTR mutation carriers without peripher

182 A8 encodes flagellar-associated polypeptide (FAP)57/WDR65, a highly conserved WD repeat, coiled coil

183 those with familial adenomatosis polyposis (FAP) or inflammatory bowel disease (IBD).

184 atients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal polyps

185 Familial Adenomatous Polyposis (FAP) is characterized by marked up-regulation of ODC in

186 ons known as familial adenomatous polyposis (FAP) or Gardner syndrome.

187 reatment for familial adenomatous polyposis (FAP) patients.

188 PC) underlie familial adenomatous polyposis (FAP), an inherited cancer syndrome characterized by the

189 efficacy in familial adenomatous polyposis (FAP), signal of benefit from imaging-based early detecti

190 amilies with familial adenomatous polyposis (FAP).

191 atients with Familial Adenomatous Polyposis (FAP).

192 atients with familial adenomatous polyposis (FAP-iPSCs) harboring germline mutations in the WNT-signa

193 us controls (familial adenomatous polyposis [FAP]).

194 muscle-resident fibro/adipogenic precursors (FAPs) are implicated in this process.

195 oy to inhibit PDGF signalling and to prevent FAP over-activation.

196 Lack of AnxA2 prevents FAP adipogenesis, protecting against adipogenic loss of

197 , including two fibro-adipogenic progenitor (FAP) cell subtypes.

198 ise to fibroblast and adipocyte progenitors (FAPs) and to their differentiated progeny, fibroblasts a

199 lite cells and fibro/adipogenic progenitors (FAPs) from muscle; satellite cells did not differentiate

200 adiaphragmatic fibro-adipogenic progenitors (FAPs) proliferate with long-term HFD feeding while givin

201 uscle-resident fibro/adipogenic progenitors (FAPs) proliferated and gave rise to adipocytes.

202 uscle-resident fibro/adipogenic progenitors (FAPs) that play a supportive role in muscle regeneration

203 lial cells and fibroadiopogenic progenitors (FAPs).

204 e referred to as fibroadipocyte progenitors (FAPs).

205 sor for the detection of folic acid protein (FAP) using graphene-based SPR chips.

206 onsisting of a fluorogen-activating protein (FAP) and a beta-fibrillizing peptide (betaFP).

207 ng to insert a fluorogen activating protein (FAP) in the EGFR extracellular domain.

208 ically encoded fluorogen-activating protein (FAP) that binds a heavy atom-substituted fluorogenic dye

209 h the use of a fluorogen-activating protein (FAP).

210 rine protease fibroblast-activating protein (FAP).

211 rine protease fibroblast activation protein (FAP) allows a selective targeting of a variety of tumors

212 ession of the fibroblast activation protein (FAP) and accumulation of the extracellular matrix (ECM)

213 e we identify fibroblast activation protein (FAP) as the enzyme that cleaves and inactivates human FG

214 Fibroblast activation protein (FAP) expression is upregulated in activated fibroblasts.

215 Fibroblast activation protein (FAP) has been established as an inducible and mesenchyma

216 Fibroblast activation protein (FAP) has emerged as an interesting molecular target used

217 Fibroblast activation protein (FAP) is a cell surface-associated serine protease up-reg

218 Fibroblast activation protein (FAP) is a marker of a major subset of CASCs in virtually

219 Fibroblast Activation Protein (FAP) is a membrane-bound serine protease whose expressio

220 Fibroblast activation protein (FAP) is a serine protease related to dipeptidyl peptidas

221 Fibroblast activation protein (FAP) is overexpressed by fibroblastlike synoviocytes in

222 Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts o

223 rine protease fibroblast activation protein (FAP) is overexpressed selectively in CAFs, drawing inter

224 Expression of fibroblast activation protein (FAP) is upregulated in stromal fibroblasts in more than

225 Fibroblast activation protein (FAP), a membrane-anchored peptidase, is highly expressed

226 expression of fibroblast activation protein (FAP), coexist within the CD49e+ CAF compartment in high-

227 rgets, namely fibroblast activation protein (FAP), macrophages, and integrin alphavbeta3.

228 that express fibroblast activation protein (FAP).

229 antly express fibroblast activation protein (FAP).

230 PP8, DPP9 and fibroblast activation protein (FAP).

231 Fluorogen-activating proteins (FAPs) are innovative fluorescent probes combining advant

232 based probes, fluorogen-activating proteins (FAPs), has been reported.

233 In vivo, we transplanted purified FAPs from transgenic, EGFP mice into the injured muscles

234 ry promoter 1B point mutations but only rare FAP-affected families carry similar mutations, the colon

235 PI-19 showed specific binding to recombinant FAP-expressing cells with high affinity.

236 nation) for preventing a clinically relevant FAP-related progression event in individuals with FAP.

237 acterized human emissions of size-segregated FAPs (1-10 mum) and total particles in a climate chamber

238 In addition, administration of a selective FAP inhibitor acutely increased circulating intact FGF21

239 ossible entry to highly potent and selective FAP inhibitors.

240 basis of our findings, we propose selective FAP inhibition as a potential therapeutic approach to in

241 light the utility of endogenous pH-sensitive FAP-receptor chimeras in high-throughput analysis of end

242 ciated with the most debilitating and severe FAP ever described, with rapid onset of tetraparesis and

243 gulator of fibrosis and is the first to show FAP's protective effects in the lung.

244 ancer have been previously described in some FAP-affected individuals with large deletions around pro

245 we concluded that glucocorticoids stimulate FAPs to differentiate into adipocytes in injured muscles

246 In contrast, Dex stimulated FAP differentiation into adipocytes.

247 pain or functional abdominal pain syndrome (FAP[S]).

248 Herein, we demonstrate that FAP(+) CASCs are required for maintenance of the provisi

249 Our findings indicate that FAP participates directly, in concert with MMPs, in coll

250 We postulate that FAP is not only a marker of disease but influences the d

251 consistent within vitrostudies showing that FAP mediates ordered proteolytic processing of matrix me

252 Clonal labeling shows that FAP(+) progenitors locally differentiate into mLNSCs.

253 results of these experiments suggested that FAP-alpha is active in parallel with RIPK3, MLKL, and p3

254 We found that FAPs produce multiple transcriptional variants of Pdgfra

255 Here we show that FAPs cause the adipogenic loss of dysferlin deficient mu

256 The FAP domain generates fluorescence that reflects IgG bind

257 king on the graphene coated SPR chip and the FAP analyte in serum.

258 for diverse applications and thus extend the FAP technology.

259 This new system decreases the size of the FAP label to ~8-12 kDa while preserving DiBs' unique pro

260 Overexpression of the FAP-low-specific transcription factor TCF21 in FAP-high

261 he film was mediated by pAG(MG) bound to the FAP.

262 Therefore, FAP is considered a promising target for radionuclide-ba

263 These FAPs dynamically produced primary cilia, structures that

264 ear-infrared excitation and emission of this FAP-TAPs provides a new spectral range for photosensitiz

265 Hh signaling through FAP cilia regulated the expression of TIMP3, a secreted

266 Thus, FAP-alpha could be a potential drug target in neutrophil

267 onal method was also successfully applied to FAP, as an overview of known FAP inhibitors confirmed ou

268 ls were used to study competitive binding to FAP, cellular uptake, internalization, and efflux of [(1

269 We show that relative to FAP, UC pouches have reduced levels of lithocholic acid

270 Binding of the tandem dye pair MG-Bis-SA to FAP-EGFR provides a ratiometric pH-sensitive model with

271 Stage-specific, "delayed time to" FAP-related events are the primary endpoints.

272 However, transplanted FAP patients have a significantly higher incidence of ea

273 the physical condition of liver transplanted FAP patients.

274 odissected in placebo- and sulindac- treated FAP patient tissue after which the methylation patterns

275 the French National Reference Center for TTR-FAP from June 1, 2013, to June 30, 2014.

276 biomarker to detect treatment effect in TTR-FAP drug trials.

277 PMNFD were all significantly reduced in TTR-FAP patients versus healthy controls, whereas TTR-noPN s

278 -type TTR staining was less prominent in TTR-FAP patients.

279 normal repeats at ATXN2 may modify AO in TTR-FAP Val30Met and may function as a risk factor.

280 ntly associated with an earlier onset in TTR-FAP Val30Met, decreasing mean AO by 6 years (95% confide

281 Cutaneous amyloid was detected in 70% of TTR-FAP and 20% of TTR-noPN subjects.

282 hyretin familial amyloid polyneuropathy (TTR-FAP).

283 ible modifier effect in AO in Portuguese TTR-FAP Val30Met families.

284 Fifteen patients with TTR-FAP underwent a complete neurologic examination, includi

285 In these 15 patients with TTR-FAP, IVCM measurement permitted rapid, noninvasive evalu

286 lace of IVCM in monitoring patients with TTR-FAP.

287 ce group for APC mutations in the unselected FAP population, we used the UMD-APC database referenced

288 valuated in radioligand binding assays using FAP-expressing HT-1080 cells.

289 By comparison with Portuguese Val30Met FAP, French Ile107Val, Ser77Tyr, and LateVal30Met FAP sh

290 nd PI3K, a serine protease activity, whereby FAP-alpha is the most likely candidate.

291 While FAP-mediated muscle fibrosis is widely studied in muscle

292 uence of relative humidity (34 vs 62%), with FAP emissions decreasing by 30-60% at higher humidity.

293 Eligible adults with FAP will be randomized to: CPP-1X 750 mg and sulindac 15

294 elated progression event in individuals with FAP.

295 s APC mutation data on 2040 individuals with FAP.

296 Participants with FAP were randomized to sulindac (150 mg) twice daily and

297 rolled trial, enrolling 92 participants with FAP, conducted from July 2010 through June 2014 at Hunts

298 Among participants with FAP, the use of sulindac and erlotinib compared with pla

299 tic mutations that put certain patients with FAP at high risk for desmoid tumors and could be future

300 64 patients with FAP underwent duodenectomy and endoscopic follow up.